You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Quest expects to deploy the pooled sample technique at its laboratories in Chantilly, Virginia and Marlborough, Massachusetts by the end of next week with additional laboratories to follow.
The Emeryville, California-based instrument maker expects to raise $178.2 million after offering 8.1 million shares at $22 per share.
The assays are performed on nasal swab specimens self-collected by patients under the observation of a healthcare provider via telemedicine.
Significant revenue from molecular and rapid diagnostic testing for SARS-CoV-2 offset declines in core lab volumes.
The firm's test detects DNA from tick-borne bacteria directly from a patient's blood, and clinical studies are planned for the 2021 tick season.
The agreement is Oncocyte's second distribution deal this year following an agreement with Core Diagnostics to sell the test in Africa and the Middle East.
Under the original March agreement, Thermo Fisher was going to pay €39 per Qiagen share, a 23 percent premium that the amendment now raises to 35 percent.
The offering consists of 8 million shares at an offering price of $40 per share, of which 2 million are being sold by a shareholder.
The firm's various COVID-19 molecular test offerings offset declines in core laboratory and point-of-care segments.
The Australian molecular diagnostics firm said it has signed agreements sell 1,025,000 of its American Depository Shares to several institutional investors.
The collaborators aim to develop lung cancer molecular diagnostic tests using molecular, clinical, and imaging-based artificial intelligence technologies.
Synlab will make a gastrointestinal testing service that is based on Microba's gut microbiome test available to its network of doctors and clinics.
The classifiers are considered reasonable and necessary if the patient can tolerate chemotherapy and it's being considered as a treatment for the patient.
The data collected could improve understanding of drug efficacy, deliver precision cancer care, guide clinical trial matching, and advance research projects.
Precommercial firm Enancio has developed lossless compression technology that Illumina hopes will cut sequencing storage costs by 80 percent for its customers.
KogeneBiotech and Trax Management's tests may be performed by any CLIA-certified high-complexity lab, while the Compass test may only be performed by its developer.
The panel tests for 23 pathogens covering 19 viruses, including SARS-CoV-2, and four bacteria that are responsible for the most frequent respiratory infections.
The firm said the New York State approval for the two tests comes soon after it launched Sema4 Signal, a family of precision oncology products and services.
The firm said it expects FDA clearance for its Acuitas AMR Gene Panel, although it has been delayed due to the agency's extended review timelines.
Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.
The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.
In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.
According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.